Epilepsy autoimmune evaluation, spinal fluid

Alphabetical Test listing

Epilepsy autoimmune evaluation, spinal fluid-12691

  
Epilepsy autoimmune evaluation, spinal fluid
  
12691
  
LAB12691
  
EPC1
  
Paraneoplastic
  
  • Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of less than 2 years using spinal fluid specimens
  • Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments:
    • Psychiatric accompaniments (psychosis, hallucinations)
    • Movement disorder (myoclonus, tremor, dyskinesias)
    • Headache
    • Cognitive impairment/encephalopathy
    • Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, premature graying of hair, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, idiopathic adrenocortical insufficiency) or "multiple sclerosis"
    • History of cancer
    • Smoking history (20+ pack years) or other cancer risk factors
    • Investigating seizures occurring within the context of a subacute multifocal neurological disorder without obvious cause, especially in a patient with past or family history of cancer
  
Cerebrospinal fluid (CSF)
  

Sterile vial/container

  
4.0 mL
  
2.0 mL
  

Sterile vial

  

Refrigerated (preferred) - 28 days

Frozen - 28 days

Ambient - 72 hrs

  
28 days
  
  • Gross hemolysis
  • Gross lipemia
  • Gross icterus
  
Mayo Clinic Laboratories (EPC2): R-NX
  
Varies
  
3 - 10 days
  

Indirect Immunofluorescence Assay (IFA), Cell Binding Assay (CBA) and Western Blot (WB) and Immunoprecipitin Assay (IPA)

  

See report

  
Negative results do not exclude autoimmune epilepsy or cancer.
  
86255 x 16
86341

Additional CPT codes (if appropriate):
84182 x 7
86255 x 4
86256 x 6
  
11/18/2014
  
07/16/2021